Board Change • May 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. Director Nils-Johan Andersson was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Apr 28
Upcoming dividend of kr4.20 per share Eligible shareholders must have bought the stock before 05 May 2026. Payment date: 11 May 2026. Payout ratio is a comfortable 74% and the cash payout ratio is 82%. Trailing yield: 5.5%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (3.9%). Reported Earnings • Apr 12
Full year 2025 earnings released: EPS: kr5.64 (vs kr6.45 in FY 2024) Full year 2025 results: EPS: kr5.64 (down from kr6.45 in FY 2024). Revenue: kr19.3b (down 5.4% from FY 2024). Net income: kr1.94b (down 13% from FY 2024). Profit margin: 10% (in line with FY 2024). Revenue is forecast to stay flat during the next 3 years compared to a 6.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Declared Dividend • Jan 31
Dividend of kr4.20 announced Dividend of kr4.20 is the same as last year. Ex-date: 5th May 2026 Payment date: 11th May 2026 Dividend yield will be 5.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (74% earnings payout ratio) and cash flows (62% cash payout ratio). The dividend has increased by an average of 13% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 16% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Jan 30
Full year 2025 earnings released: EPS: kr5.64 (vs kr6.45 in FY 2024) Full year 2025 results: EPS: kr5.64 (down from kr6.45 in FY 2024). Revenue: kr19.3b (down 5.4% from FY 2024). Net income: kr1.94b (down 13% from FY 2024). Profit margin: 10% (in line with FY 2024). Revenue is forecast to stay flat during the next 3 years compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year. Reported Earnings • Oct 26
Third quarter 2025 earnings released: EPS: kr1.35 (vs kr1.62 in 3Q 2024) Third quarter 2025 results: EPS: kr1.35 (down from kr1.62 in 3Q 2024). Revenue: kr4.69b (down 5.7% from 3Q 2024). Net income: kr465.0m (down 17% from 3Q 2024). Profit margin: 9.9% (down from 11% in 3Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to stay flat during the next 3 years compared to a 14% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 8% per year. Aankondiging • Sep 22
Hexpol AB (Publ) Announces President Changes for Hexpol Compounding Americas, Effective September 19, 2025 HEXPOL AB (publ) has appointed Kenneth Bloom as interim President of HEXPOL Compounding Americas effective September 19, 2025. Kenneth Bloom succeeds Gary Moore, who will leave the company September 19, 2025. Kenneth Bloom will act as interim President until a permanent successor has been appointed. Kenneth has previously held the position as President of HEXPOL Compounding Americas between 2020 and 2022 and before that has some 20 years of experience within the polymer industry. Reported Earnings • Jul 19
Second quarter 2025 earnings released: EPS: kr1.56 (vs kr1.90 in 2Q 2024) Second quarter 2025 results: EPS: kr1.56 (down from kr1.90 in 2Q 2024). Revenue: kr5.00b (down 8.4% from 2Q 2024). Net income: kr537.0m (down 18% from 2Q 2024). Profit margin: 11% (down from 12% in 2Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 16% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 4% per year. Aankondiging • Jun 17
HEXPOL AB (publ) to Report Q4, 2025 Results on Jan 29, 2026 HEXPOL AB (publ) announced that they will report Q4, 2025 results on Jan 29, 2026 Aankondiging • May 01
HEXPOL AB (publ) (OM:HPOL B) acquired 80% stake in Kabkom Kimya Sanayi ve Ticaret Anonim Sirketi form Erdem Eker, Özgür Ipek and Bekir Güler. HEXPOL AB (publ) (OM:HPOL B) has signed an agreement to acquire 80% stake in Kabkom Kimya Sanayi ve Ticaret Anonim Sirketi form Erdem Eker, Özgür Ipek and Bekir Güler for €54 million on February 18, 2025. The acquisition price amounts to 54 MEUR on a cash and debt free basis and is funded by a combination of bank facilities and cash. The closing will take place after regulatory approvals. HEXPOL has an option toacquire the remaining shares, and the founders have an option to sell their remaining shares to HEXPOL. For the period ending December 31, 2024, KABKOM Kimya Sanayi ve Ticaret A.S. reported total revenue of €30 million.
HEXPOL AB (publ) (OM:HPOL B) completed the acquisition of 80% stake in Kabkom Kimya Sanayi ve Ticaret Anonim Sirketi form Erdem Eker, Özgür Ipek and Bekir Güler on April 30, 2025. Reported Earnings • Apr 27
First quarter 2025 earnings released: EPS: kr1.75 (vs kr1.90 in 1Q 2024) First quarter 2025 results: EPS: kr1.75 (down from kr1.90 in 1Q 2024). Revenue: kr5.38b (up 1.3% from 1Q 2024). Net income: kr602.0m (down 8.0% from 1Q 2024). Profit margin: 11% (down from 12% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 4.1% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has remained flat. Aankondiging • Apr 26
Hexpol AB (Publ) Approves Dividend for Financial Year 2024 HEXPOL AB (publ) at its AGM held on April 25, 2025, resolved in accordance with the proposal of the Board of Directors that a dividend of SEK 4.20 per share be declared for the financial year 2024 and that the accumulated earnings be carried forward. The record date for the dividend shall be April 29, 2025. Upcoming Dividend • Apr 21
Upcoming dividend of kr4.20 per share Eligible shareholders must have bought the stock before 28 April 2025. Payment date: 05 May 2025. Payout ratio is a comfortable 65% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of British dividend payers (6.2%). In line with average of industry peers (4.9%). Aankondiging • Apr 10
HEXPOL AB (publ) (OM:HPOL B) acquired remaining 30% stake in almaak international GmbH from Olaf Eichstädt and Thomas Schmeinta. HEXPOL AB (publ) (OM:HPOL B) acquired remaining 30% stake in almaak international GmbH from Olaf Eichstädt and Thomas Schmeinta on April 9, 2025. In line with the communication at the time of acquisition of almaak in 2022, the option to purchase the remaining 30% of almaak is now exercised. Current management will remain with the company. The transaction takes place on 9 April 2025 and will be included in the second quarter of 2025.
HEXPOL AB (publ) (OM:HPOL B) completed the acquisition of remaining 30% stake in almaak international GmbH from Olaf Eichstädt and Thomas Schmeinta on April 9, 2025. Reported Earnings • Mar 26
Full year 2024 earnings released: EPS: kr6.45 (vs kr7.33 in FY 2023) Full year 2024 results: EPS: kr6.45 (down from kr7.33 in FY 2023). Revenue: kr20.4b (down 7.3% from FY 2023). Net income: kr2.22b (down 12% from FY 2023). Profit margin: 11% (in line with FY 2023). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 4.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has remained flat and the company’s share price has also remained flat. Declared Dividend • Mar 12
Dividend of kr4.20 announced Shareholders will receive a dividend of kr4.20. Ex-date: 28th April 2025 Payment date: 5th May 2025 Dividend yield will be 4.1%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (65% earnings payout ratio) and cash flows (69% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 23% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Aankondiging • Jan 29
HEXPOL AB (publ), Annual General Meeting, Apr 25, 2025 HEXPOL AB (publ), Annual General Meeting, Apr 25, 2025. Location: malmo Sweden Aankondiging • Dec 12
Hexpol Americas Announces Changes in Production Capacity and Product Portfolio HEXPOL Americas has announced changes within its product portfolio and production capacity. These changes are to optimize and create better efficiency in operations. The production site in Kennedale, Texas will be closed by the end of Q2, 2025 and all business from Kennedale will be relocated to other North American facilities. HEXPOL Americas will work closely with customers to make sure the transition is seamless. Costs associated with the closure of the production site will be accounted for in Fourth Quarter 2024. The transaction will be reported separately in Fourth Quarter 2024. HEXPOL Americas has also divested the production site in Muscle Shoals, Alabama effective immediately, to the private investment firm Karo Ventures LLC. HEXPOL Americas will work closely with Karo Ventures to make sure the transition is seamless for associates, customers and suppliers. The production site manufactured products outside of HEXPOL's core business and had an annual turnover of some 7 MUSD with a profitability level below that of the HEXPOL Group. The transaction will be reported separately in Fourth Quarter 2024, with minimal impact on the net result. Aankondiging • Nov 02
HEXPOL AB (publ) (OM:HPOL B) acquired 80% stake in Piedmont Resin Supply LLC from Matt Griffith and Paul Daniel for $86 million. HEXPOL AB (publ) (OM:HPOL B) acquired 80% stake in Piedmont Resin Supply LLC from Matt Griffith and Paul Daniel for $86 million on October 31, 2024. The acquisition price amounts to $86 million on a cash and debt free basis and is funded by a combination of bank facilities and cash.
HEXPOL AB (publ) (OM:HPOL B) completed the acquisition of 80% stake in Piedmont Resin Supply LLC from Matt Griffith and Paul Daniel on October 31, 2024. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: kr1.62 (vs kr1.95 in 3Q 2023) Third quarter 2024 results: EPS: kr1.62 (down from kr1.95 in 3Q 2023). Revenue: kr4.98b (down 8.9% from 3Q 2023). Net income: kr559.0m (down 17% from 3Q 2023). Profit margin: 11% (down from 12% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 6.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 2% per year and the company’s share price has also increased by 2% per year. Aankondiging • Aug 19
HEXPOL AB (publ) to Report Q4, 2024 Results on Jan 28, 2025 HEXPOL AB (publ) announced that they will report Q4, 2024 results on Jan 28, 2025 Reported Earnings • Jul 18
Second quarter 2024 earnings released: EPS: kr1.90 (vs kr1.97 in 2Q 2023) Second quarter 2024 results: EPS: kr1.90 (down from kr1.97 in 2Q 2023). Revenue: kr5.45b (down 4.8% from 2Q 2023). Net income: kr654.0m (down 3.7% from 2Q 2023). Profit margin: 12% (in line with 2Q 2023). Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 6.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 3% per year. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: kr1.90 (vs kr1.94 in 1Q 2023) First quarter 2024 results: EPS: kr1.90 (down from kr1.94 in 1Q 2023). Revenue: kr5.31b (down 11% from 1Q 2023). Net income: kr654.0m (down 2.1% from 1Q 2023). Profit margin: 12% (up from 11% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, compared to a 2.5% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 6% per year. Upcoming Dividend • Apr 22
Upcoming dividend of kr6.00 per share Eligible shareholders must have bought the stock before 29 April 2024. Payment date: 06 May 2024. Payout ratio is a comfortable 55% and this is well supported by cash flows. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (6.0%). In line with average of industry peers (2.9%). Buy Or Sell Opportunity • Apr 17
Now 21% undervalued Over the last 90 days, the stock has risen 16% to kr132. The fair value is estimated to be kr167, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 2.2% per annum. Earnings are also forecast to grow by 4.3% per annum over the same time period. Reported Earnings • Mar 27
Full year 2023 earnings released: EPS: kr7.33 (vs kr7.21 in FY 2022) Full year 2023 results: EPS: kr7.33 (up from kr7.21 in FY 2022). Revenue: kr22.0b (flat on FY 2022). Net income: kr2.52b (up 1.7% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 4.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 10% per year. Declared Dividend • Mar 27
Dividend increased to kr6.00 Dividend of kr6.00 is 67% higher than last year. Ex-date: 29th April 2024 Payment date: 6th May 2024 Dividend yield will be 4.6%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (55% earnings payout ratio) and cash flows (48% cash payout ratio). The dividend has increased by an average of 21% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 13% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Mar 22
Now 20% undervalued Over the last 90 days, the stock has risen 6.5% to kr130. The fair value is estimated to be kr163, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 2.1% per annum. Earnings are also forecast to grow by 4.0% per annum over the same time period. Reported Earnings • Jan 27
Full year 2023 earnings released: EPS: kr7.33 (vs kr7.21 in FY 2022) Full year 2023 results: EPS: kr7.33 (up from kr7.21 in FY 2022). Revenue: kr22.0b (flat on FY 2022). Net income: kr2.52b (up 1.7% from FY 2022). Profit margin: 11% (in line with FY 2022). Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Jan 05
Now 21% undervalued Over the last 90 days, the stock is up 27%. The fair value is estimated to be kr150, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Earnings per share has grown by 20%. For the next 3 years, revenue is forecast to grow by 1.3% per annum. Earnings is also forecast to grow by 2.7% per annum over the same time period. Aankondiging • Nov 14
HEXPOL AB (publ) (OM:HPOL B) acquired Star Thermoplastic Alloys & Rubbers, Inc. from Thomas A. Dieschbourg for $26.5 million. HEXPOL AB (publ) (OM:HPOL B) acquired Star Thermoplastic Alloys & Rubbers, Inc. from Thomas A. Dieschbourg for $26.5 million on November 1, 2023. The acquisition price amounts to $26.5 million on a cash and debt free basis and is funded by a combination of cash on hand and existing bank facilities. As on November 14, 2023, Star Thermoplastic Alloys & Rubbers, Inc. reported a revenue of approximately $20 million for the year ended December 31, 2022.
HEXPOL AB (publ) (OM:HPOL B) completed the acquisition of Star Thermoplastic Alloys & Rubbers, Inc. from Thomas A. Dieschbourg on November 1, 2023. Reported Earnings • Oct 28
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr5.46b (down 7.8% from 3Q 2022). Net income: kr670.0m (up 8.9% from 3Q 2022). Profit margin: 12% (up from 10% in 3Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 2.2% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. Aankondiging • Sep 03
HEXPOL AB (publ), Annual General Meeting, Apr 26, 2024 HEXPOL AB (publ), Annual General Meeting, Apr 26, 2024. Buying Opportunity • Aug 08
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 8.0%. The fair value is estimated to be kr135, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to decline by 2.4% in 2 years. Earnings is forecast to grow by 5.4% in the next 2 years. Buying Opportunity • Jul 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be kr136, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 26%. Revenue is forecast to decline by 1.4% in 2 years. Earnings is forecast to grow by 6.1% in the next 2 years. Reported Earnings • Jul 20
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr5.73b (up 1.3% from 2Q 2022). Net income: kr679.0m (up 5.4% from 2Q 2022). Profit margin: 12% (in line with 2Q 2022). Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 7.5% decline forecast for the Chemicals industry in the United Kingdom. Buying Opportunity • Jun 09
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be kr145, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 1.2% in 2 years. Earnings is forecast to grow by 7.8% in the next 2 years. Buying Opportunity • May 24
Now 22% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be kr145, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 1.5% in 2 years. Earnings is forecast to grow by 7.4% in the next 2 years. Buying Opportunity • May 04
Now 20% undervalued The stock has been flat over the last 90 days. The fair value is estimated to be kr147, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 1.5% in 2 years. Earnings is forecast to grow by 7.4% in the next 2 years. Reported Earnings • Apr 29
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr5.99b (up 16% from 1Q 2022). Net income: kr668.0m (up 11% from 1Q 2022). Profit margin: 11% (in line with 1Q 2022). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Upcoming Dividend • Apr 25
Upcoming dividend of kr3.60 per share at 2.8% yield Eligible shareholders must have bought the stock before 02 May 2023. Payment date: 08 May 2023. Payout ratio is a comfortable 50% and this is well supported by cash flows. Trailing yield: 2.8%. Lower than top quartile of British dividend payers (5.8%). Higher than average of industry peers (2.3%). Reported Earnings • Jan 27
Full year 2022 earnings released: EPS: kr7.21 (vs kr6.85 in FY 2021) Full year 2022 results: EPS: kr7.21 (up from kr6.85 in FY 2021). Revenue: kr22.2b (up 39% from FY 2021). Net income: kr2.48b (up 5.3% from FY 2021). Profit margin: 11% (down from 15% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Dec 13
Now 21% undervalued Over the last 90 days, the stock is up 20%. The fair value is estimated to be kr144, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.0% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to grow by 13% in 2 years. Earnings is forecast to grow by 21% in the next 2 years. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Gun Nilsson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Aankondiging • Oct 22
HEXPOL AB (publ) to Report Q4, 2022 Results on Jan 27, 2023 HEXPOL AB (publ) announced that they will report Q4, 2022 results at 12:00 PM, Central European Standard Time on Jan 27, 2023 Reported Earnings • Oct 21
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr5.92b (up 44% from 3Q 2021). Net income: kr615.0m (down 27% from 3Q 2021). Profit margin: 10% (down from 21% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to stay flat during the next 3 years compared to a 8.8% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jul 16
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr5.65b (up 41% from 2Q 2021). Net income: kr644.0m (up 20% from 2Q 2021). Profit margin: 11% (down from 13% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 8.3% compared to a 16% decline forecast for the industry in the United Kingdom. Reported Earnings • Apr 30
First quarter 2022 earnings released First quarter 2022 results: Revenue: kr5.17b (up 36% from 1Q 2021). Net income: kr600.0m (up 12% from 1Q 2021). Profit margin: 12% (down from 14% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 18% compared to a 14% decline forecast for the industry in the United Kingdom. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. Independent Director Gun Nilsson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • Apr 22
Upcoming dividend of kr6.00 per share Eligible shareholders must have bought the stock before 29 April 2022. Payment date: 05 May 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 3.3%. Lower than top quartile of British dividend payers (4.6%). Higher than average of industry peers (2.6%). Reported Earnings • Apr 08
Full year 2021 earnings released: EPS: kr6.85 (vs kr4.09 in FY 2020) Full year 2021 results: EPS: kr6.85 (up from kr4.09 in FY 2020). Revenue: kr16.0b (up 19% from FY 2020). Net income: kr2.36b (up 67% from FY 2020). Profit margin: 15% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14% compared to a 15% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Jan 30
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: kr6.85 (up from kr4.09 in FY 2020). Revenue: kr16.0b (up 19% from FY 2020). Net income: kr2.36b (up 67% from FY 2020). Profit margin: 15% (up from 11% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 13% compared to a 3.5% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 10% per year. Buying Opportunity • Jan 18
Now 21% undervalued Over the last 90 days, the stock is up 5.4%. The fair value is estimated to be kr139, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 4.5% per annum over the last 3 years. Board Change • Dec 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Director Gun Nilsson was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 23
Third quarter 2021 earnings released The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr4.11b (up 23% from 3Q 2020). Net income: kr841.0m (up 97% from 3Q 2020). Profit margin: 21% (up from 13% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Recent Insider Transactions • Aug 13
Insider recently sold kr6.0m worth of stock On the 10th of August, Carsten Rüter sold around 50k shares on-market at roughly kr119 per share. In the last 3 months, there was an even bigger sale from another insider worth kr33m. Insiders have been net sellers, collectively disposing of kr50m more than they bought in the last 12 months. Recent Insider Transactions • Aug 03
President & CEO recently sold kr33m worth of stock On the 29th of July, Georg Brunstam sold around 290k shares on-market at roughly kr115 per share. This was the largest sale by an insider in the last 3 months. Georg has been a seller over the last 12 months, reducing personal holdings by kr38m. Reported Earnings • Jul 18
Second quarter 2021 earnings released: EPS kr1.56 (vs kr0.35 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: kr4.00b (up 58% from 2Q 2020). Net income: kr537.0m (up 340% from 2Q 2020). Profit margin: 13% (up from 4.8% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Reported Earnings • Apr 30
First quarter 2021 earnings released The company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: kr3.81b (down 8.6% from 1Q 2020). Net income: kr534.0m (up 32% from 1Q 2020). Profit margin: 14% (up from 9.7% in 1Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Upcoming Dividend • Apr 22
Upcoming dividend of kr2.30 per share Eligible shareholders must have bought the stock before 29 April 2021. Payment date: 05 May 2021. Trailing yield: 2.2%. Lower than top quartile of British dividend payers (4.1%). Higher than average of industry peers (1.6%). Reported Earnings • Apr 05
Full year 2020 earnings released: EPS kr4.09 (vs kr4.48 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr13.4b (down 13% from FY 2019). Net income: kr1.41b (down 8.6% from FY 2019). Profit margin: 11% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 01
New 90-day high: kr93.88 The company is up 17% from its price of kr80.40 on 03 November 2020. The British market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr112 per share. Reported Earnings • Jan 31
Full year 2020 earnings released: EPS kr4.09 (vs kr4.48 in FY 2019) The company reported a poor full year result with weaker earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: kr13.4b (down 13% from FY 2019). Net income: kr1.41b (down 8.6% from FY 2019). Profit margin: 11% (in line with FY 2019). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Analyst Estimate Surprise Post Earnings • Jan 31
Revenue beats expectations Revenue exceeded analyst estimates by 0.9%. Over the next year, revenue is forecast to grow 6.1% compared to a 11% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Jan 13
New 90-day high: kr91.80 The company is up 6.0% from its price of kr86.85 on 15 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr106 per share. Recent Insider Transactions • Jan 01
President & CEO recently sold kr4.9m worth of stock On the 28th of December, Georg Brunstam sold around 55k shares on-market at roughly kr88.74 per share. This was the largest sale by an insider in the last 3 months. This was Georg's only on-market trade for the last 12 months. Is New 90 Day High Low • Dec 29
New 90-day high: kr90.55 The company is up 14% from its price of kr79.70 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr108 per share. Is New 90 Day High Low • Nov 11
New 90-day high: kr89.95 The company is up 43% from its price of kr63.05 on 12 August 2020. The British market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr93.56 per share. Reported Earnings • Oct 25
Third quarter earnings released Over the last 12 months the company has reported total profits of kr1.29b, down 20% from the prior year. Total revenue was kr13.8b over the last 12 months, down 9.8% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 25
Third-quarter earnings released: Revenue misses expectations Third-quarter revenue missed analyst estimates by 4.5% at kr3.33b. Revenue is forecast to grow 1.4% over the next year, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom. Is New 90 Day High Low • Oct 16
New 90-day high: kr87.60 The company is up 37% from its price of kr64.00 on 17 July 2020. The British market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr90.87 per share. Is New 90 Day High Low • Oct 01
New 90-day high: kr81.10 The company is up 18% from its price of kr69.00 on 03 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is kr81.52 per share. 
